Multiple risk factors have been associated with the onset of ICANS, including pre-existing neurological conditions, a prior occurrence of CRS, elevated CAR T-cell doses and peak expansion rates, high tumor burden at the time of infusion, reduced platelet counts, and elevated levels of inflammatory markers, such as C-reactive protein (CRP), ferritin, and cytokines including IL-1, IL-6, IL-10, and interferon-gamma [14,15]. This evidence concerns the gene CRP and neoplasm.